+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
ID07869823

Study of Cemiplimab and Quad Shot Radiation in Frail or Elderly Patients with Advanced Skin Squamous Cell Carcinoma of the Head and Neck

Led by Vanderbilt-Ingram Cancer Center · Updated on 2026-10-13

25

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the combination of the drug cemiplimab with a short course of radiation therapy called Quad Shot in elderly or frail patients who have advanced squamous cell carcinoma of the skin in the head and neck area. The main goal is to see if healthcare providers can successfully deliver at least six doses of cemiplimab and three rounds of Quad Shot radiation to these patients. Participants will receive cemiplimab intravenously every three weeks for up to eight doses or until disease progression or side effects require stopping. Radiation therapy is given using the Quad Shot technique, which includes two treatments per day over two days, repeated every three weeks for up to four cycles. Patients who respond well after three cycles may stop radiation early. During the study, participants will be monitored for treatment delivery and side effects for about one year. Researchers will assess how many patients receive the planned treatments and measure responses. Various lab tests, imaging, and tumor tissue analyses will support evaluation. The study is sponsored by Vanderbilt-Ingram Cancer Center and aims to improve care options for patients who are unfit for standard surgery or radiation.

CONDITIONS

Brief Title

Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck

Research Team

B

Barbara Murphy, M.D.

Z

Zachary Kohutek, M.D., Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here